Dendreon Corp fka DNDNQ

[ocyanblue]

PGS - ? on safety data

Since adverse events can/do develop over time, it makes sense that that data should be periodically monitored. However, from the point of view of reviewing a BLA/NDA for approval, what is the convention for freezing data collection for analysis? Whatever is in front of the reviewers at the time? Endpoints reached? Trial terminated? Etc. Thanks.